Cadrenal Therapeutics Common Stock Statistics
Share Statistics
Cadrenal Therapeutics Common Stock has 1.66M shares outstanding. The number of shares has increased by -91.8% in one year.
| Shares Outstanding | 1.66M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -93.33% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.03M |
| Failed to Deliver (FTD) Shares | 90 |
| FTD / Avg. Volume | 0.14% |
Short Selling Information
The latest short interest is 39.48K, so 2.38% of the outstanding shares have been sold short.
| Short Interest | 39.48K |
| Short % of Shares Out | 2.38% |
| Short % of Float | 5.83% |
| Short Ratio (days to cover) | 0.65 |
Valuation Ratios
The PE ratio is -1.15 and the forward PE ratio is -3.76.
| PE Ratio | -1.15 |
| Forward PE | -3.76 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.25 |
| P/FCF Ratio | -2.73 |
| PEG Ratio | n/a |
Enterprise Valuation
Cadrenal Therapeutics Inc. Common Stock has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 10.27, with a Debt / Equity ratio of 0.
| Current Ratio | 10.27 |
| Quick Ratio | 10.27 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.28 |
| Cash Flow / Debt | -165.35 |
| Interest Coverage | -446.34 |
Financial Efficiency
Return on equity (ROE) is -1.09% and return on capital (ROIC) is -98.95%.
| Return on Equity (ROE) | -1.09% |
| Return on Assets (ROA) | -0.98% |
| Return on Capital (ROIC) | -98.95% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.09M |
| Employee Count | 4 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 46.41% in the last 52 weeks. The beta is 0, so Cadrenal Therapeutics Common Stock's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | 46.41% |
| 50-Day Moving Average | 14.64 |
| 200-Day Moving Average | 9.53 |
| Relative Strength Index (RSI) | 35.59 |
| Average Volume (20 Days) | 63.27K |
Income Statement
In the last 12 months, Cadrenal Therapeutics Common Stock had revenue of $0 and earned -$8.36M in profits. Earnings per share was $-9.63.
| Revenue | 0 |
| Gross Profit | -1.98K |
| Operating Income | -7.63M |
| Net Income | -8.36M |
| EBITDA | -8.34M |
| EBIT | - |
| Earnings Per Share (EPS) | -9.63 |
Balance Sheet
The company has $8.40M in cash and $21.35K in debt, giving a net cash position of $8.38M.
| Cash & Cash Equivalents | 8.40M |
| Total Debt | 21.35K |
| Net Cash | 8.38M |
| Retained Earnings | -15.07M |
| Total Assets | 4.68M |
| Working Capital | 3.41M |
Cash Flow
In the last 12 months, operating cash flow was -$3.53M and capital expenditures -$3.25K, giving a free cash flow of -$3.53M.
| Operating Cash Flow | -3.53M |
| Capital Expenditures | -3.25K |
| Free Cash Flow | -3.53M |
| FCF Per Share | -4.07 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
CVKD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -85.98% |
| FCF Yield | -19.02% |
Analyst Forecast
The average price target for CVKD is $46, which is 310.7% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $46 |
| Price Target Difference | 310.7% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Aug 20, 2024. It was a backward split with a ratio of 1:15.
| Last Split Date | Aug 20, 2024 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -1.86 |
| Piotroski F-Score | 2 |